CV Sciences Q3 2024 revenue $3.9M, gross margin 46%, adjusted EBITDA loss of $75k

CV Sciences, Inc.

2024-Q3 EPS reported -$0.01 revenue$11,821,000

Revenue $3.9M, down 5% YoY from $4.1M; B2B sales fell 9% due to state CBD regulations.
Gross margin improved to 46.0% from 45.1% YoY; operating loss narrowed to $0.3M from $0.4M.
Adjusted EBITDA loss of $75k, near breakeven versus $0.4M loss a year ago.
Cash balance $1.0M at quarter end; secured $0.9M net proceeds from Streeterville financing.
Launched +PlusHLTH supplement line (CLARITY, PEACE, RESHAPE) and new pet chews.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.